Through an exclusive license agreement, Iveric Bio will develop and commercialize new formulations of Zimura using silica-based sustained release technology by DelSiTech, according to a press release from Iveric Bio.
The agreement coincides with Iveric Bio’s lifecycle expansion plan for Zimura (avacincaptad pegol), as the company is looks to develop sustained release technologies for the treatment of age-related macular degeneration. According to the release, these technologies may be able to address patients being treated for geographic atrophy (GA) and intermediate AMD.
Iveric Bio plans